Oncology-focused VC, deep expertise
Profile being verified
What they look for
An oncology-focused VC, where the scientific expertise of the reference partner is decisive. They look at clinical data, endpoints, and potential licensing deals with big pharma.
What puts them off
Insufficient preclinical data, no defined CMC, unrealistic clinical timeline.
How to approach them
Via oncology Key Opinion Leaders (KOLs) or the Swiss big pharma network. Highly specialised.
Decision process
3–6 months of in-depth scientific due diligence.
Recent investments
Oncology biotech in Phase I–II, focus on immuno-oncology and ADCs.